ProCE Banner Activity

Filgotinib Demonstrates Favorable Safety in Pooled Analysis of Phase III Studies in Patients With Rheumatoid Arthritis

Slideset Download
Conference Coverage
Results of this pooled analysis of 3 randomized, controlled phase III trials show filgotinib to be well tolerated, with no new safety signals, and low rates of MACE/VTE.

Released: November 18, 2019

Expiration: November 16, 2020

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Gilead

Mallinckrodt Pharmaceuticals